Single-cell analysis of differences in transcriptomic profiles of oocytes and cumulus cells at GV, MI, MII stages from PCOS patients

Qiwei Liu1,*, Yumei Li1,*, Yun Feng3, Chaojie Liu3, Jieliang Ma3, Yifei Li3, Huifen Xiang4, Yazhong Ji5, Yunxia Cao4, Xiaowen Tong1 & Zhigang Xue3

Polycystic ovary syndrome (PCOS) is a common frequent endocrine disorder among women of reproductive age. Although assisted reproductive techniques (ARTs) are used to address subfertility in PCOS women, their effectiveness is not clear. Our aim was to compare transcriptomic profiles of oocytes and cumulus cells (CCs) between women with and without PCOS, and assess the effectiveness of ARTs in treating PCOS patients. We collected oocytes and CCs from 16 patients with and without PCOS patients to categorize them into 6 groups according to oocyte nuclear maturation. Transcriptional gene expression of oocyte and CCs was determined via single-cell RNA sequencing. The ratio of fertilization and cleavage was higher in PCOS patients than in non-PCOS patients undergoing ARTs, and there was no difference in the number of high-quality embryos between the groups. Differentially expressed genes including PPP2R1A, PDGFRA, EGFR, GJA1, PTGS2, TNFAIP6, TGF-β1, CAV1, INHBB et al. were investigated as potential causes of PCOS oocytes and CCs disorder at early stages, but their expression returned to the normal level at the metaphase II (MII) stage via ARTs. In conclusion, ARTs can improve the quality of cumulus-oocyte complex (COC) and increase the ratio of fertilization and cleavage in PCOS women.

Polycystic ovary syndrome (PCOS) is one of the most frequent endocrine disorders in women of reproductive age, characterized by hyperandrogenemia, oligo-ovulation or anovulation, and polycystic ovaries1. PCOS affects 5–20% of reproductive women and causes subfertility in 50% of them2. Various methods are used to address subfertility in this population, including lifestyle modifications, ovulation induction, laparoscopic ovarian drilling, and assisted reproductive techniques (ARTs).

ARTs are increasingly used as primary treatment; however, whether ARTs improve oocyte quality and further results such as fertilization, cleavage, embryo and pregnancy in PCOS patients has long been controversial. Some studies have shown that ARTs can improve fertilization, cleavage, implantation, clinical pregnancy, and live-birth rates in women with PCOS, and patients with PCOS had similar or better pregnancy rates when comparing with control3–5. Wang et al. compared clinic outcomes of 2632 PCOS women with 28523 non-PCOS women undergoing ARTs, and found that there are higher number of available embryo and clinic pregnancy rate in PCOS women than in non-PCOS6. A meta-analysis showed that birth and implantation rates were higher in PCOS patients than in controls using in vitro maturation7. Heijnen et al. also reported PCOS and control patients undergoing conventional in vitro fertilization had similar pregnancy and live birth rates8. But others have been concerned that ARTs may decrease the quality of oocytes and delay the mutation process of oocytes in PCOS patients9–12. Previous studies used microarrays to analyze genes that are differentially expressed in cumulus cells (CCs) between PCOS patients and control patients. EREG, AREG, ERK1/2, MAP3K4, LHCGR and TNVIK, among others, were related to...
patients, LH/FSH (0.72 ± 0.9) was significantly higher in the PCOS group (5.4 ± 0.3) than in the non-PCOS groups, (2.5 ± 0.7). Mean testosterone levels, LH (6.1 ± 0.8) was significantly higher in the PCOS group (9.3 ± 0.6) than control patients, LH/FSH (0.9 ± 0.4) was significantly higher than that in the non-PCOS patients (1.3 ± 0.5). Mean testosterone levels, total ovarian volume, the mean number of aspirated oocytes, and the ratio of oosperm and cleavage were significantly higher in the PCOS group (345.9 ± 1800.8, 20, 80.1 ± 17.2, 79.4 ± 18.6, respectively) than in the non-PCOS group (373.7 ± 1863.7, 14, 20). The aim of this study was to compare the development of COCs between women with and without PCOS undergoing ARTs, which can help us assess the impact of ARTs on fertility in PCOS patients. The results may inform the appropriate use of ARTs in subfertile PCOS patients in clinical treatment.

### Results

#### Clinical characteristics and biochemical characteristics of PCOS and control subjects.

The clinical and biochemical characteristics of 42 non-PCOS patients and 42 PCOS patients who participated in this study are shown in Table 1. There was statistically significant difference between the two groups in age, body mass index (BMI), luteinizing hormone (LH), follicle-stimulating hormone (FSH), systolic blood pressure, diastolic blood pressure, insulin, total gonadotropin dose, androstenedione, sex hormone-binding globulin, mature oocytes, or high-quality embryos. Patients with PCOS had a higher ratio of basic LH/FSH (1.4 ± 0.9) and LH (9.3 ± 6.1) than control patients, LH/FSH (0.72 ± 0.30) and LH (4.8 ± 2.5), P < 0.001. The mean number of antral follicles in the PCOS patients (>24) was significantly higher than that in the non-PCOS patients (13 ± 5). Mean testosterone levels, total ovarian volume, the mean number of aspirated oocytes, and the ratio of oosperm and cleavage were significantly higher in the PCOS group (345.9 ± 1800.8, 20, 80.1 ± 17.2, 79.4 ± 18.6, respectively) than in the non-PCOS group (373.7 ± 1863.7, 14, 71.4 ± 21.7, 70.0 ± 21.7, respectively).

#### Profiles of differentially expressed genes in human CCs and oocytes.

Unsupervised clustering showed differential CC and oocyte gene expression between PCOS patients and controls (Figs 1 and 2). In class I (PCOS oocytes versus normal oocytes at the GV stage), 156 genes were upregulated (fold change [FC], from 3 to 8), and 450 genes were downregulated (FC, from -3 to -7). In class II (PCOS oocytes versus normal oocytes at the MI stage), 184 genes were upregulated (FC, from 2 to 5), and 253 genes were downregulated (FC, from -2 to -6). Last, in class III (PCOS oocytes versus normal oocytes at the MII stage), 487 genes were upregulated (FC, from 3 to 7), and 352 genes were downregulated (FC, from -3 to -8). When CCs were compared between the PCOS and non-PCOS groups, 4371, 1587, and 2450 upregulated genes, as well as 985, 780, and 1504 downregulated genes

| Non-PCOS (n = 42, number of patients) | PCOS (n = 42, number of patients) | P-value |
|--------------------------------------|----------------------------------|---------|
| Age (years)                          | 28.5 ± 3.75                      | 27.4 ± 3.02 | 0.059 |
| BMI (Kg/m²)                          | 22.7 ± 3.1                       | 22.7 ± 3.9 | 0.929 |
| SBP (mmHg)                           | 113.0 ± 8.4                      | 115.3 ± 9.1 | 0.148 |
| DBP (mmHg)                           | 74.8 ± 6.5                       | 75.3 ± 8.1 | 0.830 |
| AFC (antral follicle)                | 13 ± 5                           | >24       | <0.001 (0.000)** |
| FSH (mIU/ml)                         | 6.7 ± 1.7                        | 6.3 ± 1.3 | 0.254 |
| LH (mIU/ml)                          | 4.8 ± 2.5                        | 9.3 ± 6.1 | <0.001 (0.000)** |
| LH/FSH                               | 0.72 ± 0.3                       | 1.4 ± 0.9 | <0.001 (0.000)** |
| Insulin                              | 10.6 ± 4.5 (n = 30)              | 15.1 ± 11.8 (n = 30) | 0.143 |
| Total gonadotropin dose              | 2175.0 ± 699.3                   | 2068 ± 1035.8 | 0.580 |
| Testosterone (nmol/L)                | 1.1 ± 0.6 (n = 40)               | 1.4 ± 0.7 (n = 40) | <0.05 (0.01)** |
| androstenedione                      | 2.3 ± 0.8 (n = 29)               | 2.2 ± 0.7 (n = 29) | 0.931 |
| SHBG (nmol/L)                        | 44.8 ± 19.9 (n = 28)             | 49.7 ± 34.6 (n = 28) | 0.519 |
| oligoamenorrhoea                     | 0                                | 12        | <0.001 (0.000)** |
| Ovarian volume total                 | 3737.0 ± 1863.7                  | 5475.9 ± 1800.8 | <0.001 (0.000)** |
| Right                                | 2053.4 ± 1189.2                  | 2964.9 ± 1081.9 | <0.001 (0.000)** |
| Left                                 | 1683.6 ± 899.7                   | 2511.0 ± 950.0 | <0.001 (0.000)** |
| No. of aspirated oocytes             | 14                               | 20        | <0.001 (0.007)** |
| % of mature oocyte (MII)             | 84.8 ± 19.6                      | 90.1 ± 15.2 | 0.182 |
| % of oosperm                         | 71.4 ± 21.7                      | 80.1 ± 17.2 | <0.001 (0.04)** |
| % of cleavage                        | 70.0 ± 21.7                      | 79.4 ± 18.6 | <0.001 (0.033)** |
| % of high-quality embryo             | 31.2 ± 17.0                      | 37.9 ± 16.8 | 0.07 |

Table 1. Clinical characteristics and outcome of patients with and without PCOS. *P < 0.05, **P < 0.001, non-PCOS VS PCOS group. BMI, Body Mass Index. SBP, Systolic Blood Pressure. DBP, Diastolic Blood Pressure. FSH, Follicle Stimulating Hormone. LH, Luteinizing Hormone. SHBG, Sex Hormone Binding Globulin.
were found in class IV (PCOS CCs versus normal CCs at the GV stage), class V (PCOS CCs versus normal CCs at the MI stage), and class VI (PCOS CCs versus normal CCs at the MII stage), respectively (FC $>$ 3 or FC $<$ −3) (Table 2).

**Figure 1. Heatmap of differentially expressed genes in oocytes with and without PCOS at GV, MI, MII stage.** Green corresponds to up-expressed genes; red corresponds to down-expressed genes. NO-GV, oocyte at GV stage from normal women; PO-GV, oocyte at GV stage from women with PCOS; NO-MI, oocyte at MI stage from normal women; PO-MI, oocyte at MI stage from women with PCOS; NO-MII, oocyte at MII stage from normal women; PO-MII, oocyte at MII stage from women with PCOS.

**Signal transduction pathways in oocytes and CCs from women with and without PCOS.** The functional enrichment analysis based on data from the Kyoto Encyclopedia of Genes and Genomes (KEGG) revealed that differentially expressed genes in PCOS oocytes were mainly involved in the PI3K-Akt signaling pathway, gap junction pathway, calcium signaling pathway, and oocyte meiosis pathway (adjusted P value ($P_{adj}$) < 0.05) (Fig. 3A), indicating those pathways may play important role in oocyte maturation. PI3K-Akt signaling pathway and gap junction pathway included 4 differential expressed genes in PCOS oocyte which were related to oocyte development respectively, while each calcium signaling pathway and oocyte meiosis pathway contained 2 differential expressed genes. In PCOS CCs, the differentially expressed genes were mainly involved in the MAPK signaling pathway, steroid hormone biosynthesis pathway, transforming growth factor, beta (TGF-β) signaling pathway, vascular endothelial growth factor (VEGF) signaling pathway, and PI3K-Akt signaling pathway ($P_{adj}$ < 0.05) (Fig. 3B). Briefly, we found 3 differentially expressed genes in steroid hormones pathway that are associated with COCs proliferation and maturation in PCOS CCs. We also found 2 differentially expressed genes in each of MAPK signaling pathway, TGF-β signaling pathway, VEGF signaling pathway, and PI3K-Akt signaling pathway.

**Differentially expressed genes in PCOS oocytes related to meiosis, gap junction, hormone receptor signaling, DNA repairing and secreted factors.** Next, genes with significantly differential expression in PCOS oocytes compared with non-PCOS oocytes were analyzed ($P_{adj}$ < 0.05) (Fig. 4A). Many genes related with oocyte meiosis and maturation were differentially expressed in PCOS oocytes compared with non-PCOS oocytes, including epidermal growth factor receptor (EGFR), progesterone receptor (PGR), progesterone receptor membrane component 1 (PGRMC1), phospholipase C, zeta 1 (PLCZ1), secreted frizzled-related protein 4 (SFRP4), and zinc finger, MIZ-type containing 1 (ZMIZ1) and zinc finger and SCAN domain containing 4 (ZSCAN4) (Fig. 5A). These genes that stimulate the meiosis process and oocyte maturation were significantly downregulated at the GV stage in PCOS oocytes compared with control oocytes, but their expression was recovered and normal at the MI and MII stages. Several genes that regulate cell-cell communication were downregulated in PCOS CCs compared with control CCs, such as the integrin (ITG) family (subunits ITGAX, ITGAV, ITGA1, ITGA4, and ITGA6) and gap junction protein alpha 1 (GJA1/CX43) at three stages (Fig. 5B). Hormone receptors were differentially expressed in PCOS oocytes compared with non-PCOS oocytes at the mutational
stage, including anti-Müllerian hormone receptor, type II (AMHR2), LHCGR, oxytocin receptor (OXTR) and K (lysine) acetyltransferase 2B (KAT2B) (Fig. 5C). The expression of genes related to DNA repair, including inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta, ligase I, DNA, ATP-dependent, and X-ray repair complementing defective repair in Chinese hamster cells 1 (XRCC1), was higher in PCOS oocytes than in normal oocytes at early phases, but the expression of these genes was normal at the MII phase (Fig. 5D). Genes related to secreted factors, such as subunit alpha of protein phosphatase 2A (PPP2R1A), platelet-derived growth factor receptor, alpha polypeptide (PDGFRA), and NOBOX oogenesis homeobox (NOBOX) were differentially expressed; however, the expression of these secreted genes was normal at the maturation phase (Fig. 5E).

Differentially expressed genes in PCOS CCs related to cell proliferation, hormone receptor signaling, folliculogenesis, gap junction, and oxidative stress. Genes with significantly differential expression in PCOS CCs when comparing with non-PCOS CCs were analyzed (Fig. 4B). Among many genes that are involved in cell proliferation, several genes were deregulated in PCOS CCs compared with non-PCOS CCs, including prostaglandin-endoperoxide synthase 2 (PTGS2), tumor necrosis factor-alpha-induced protein 6 (TNFαIP6), TGF-β2, caveolin 1 (CAV1), inhibin, beta B (INHβB), EGFR, and inhibitor of DNA binding 3 (ID3) (Fig. 6A). At the GV stage, all these genes were overexpressed in PCOS CCs, which suggests CCs proliferated in PCOS patients.
were overexpressed; however, there was no difference in expression at later stages. Genes related to hormone receptors, including phospholipase A2 group IVA (PLA2G4A); 24-dehydrocholesterol reductase (DHCR24); cytochrome P450, family 1, subfamily B, polypeptide 1 (CYP1B1); prostaglandin E receptor 2 (PTGER2); PTGER4; hydroxysteroid dehydrogenase like 2 (HSDL2); cytochrome P450, family 11, subfamily A, polypeptide 1 (CYP11A1); superoxide dismutase 1 (SOD1); and nitric oxide synthase 3 (NOS3), were significantly differentially expressed in PCOS patients compared with non-PCOS patients at baseline (Fig. 6B). And genes that impact the maturation of follicles and oocytes were also deregulated in PCOS CCs compared with non-PCOS CCs (Fig. 6C). These genes included TNFα, IP6, inner mitochondrial membrane peptidase subunit 2 (IMMP2L), neuropilin 1 (NRP1), TGF-β1, and interleukin 6 (IL6). Several genes that regulate cell–cell communication were upregulated at the GV phase and normal or downregulated at the MI and MII stages in PCOS CCs compared with control CCs. These included gap junction protein, alpha 5 (GJA5), sphingosine-1-phosphate receptor 1 (S1PR1), Smoothened (SMO), EGFR, ITGA6, and NOTCH2 (Fig. 6D). Many genes were reported can be prediction genes for the quality of embryo. In our study, Gremlin-1 (GREM1), fas cell surface death receptor (FAS), and superoxide dismutase 1 (SOD1), which have been shown to predict the quality of oocytes, were differentially expressed in PCOS CCs compared with control CCs. Last, genes related to oxidative stress, NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 1 (NDUFA1) and peroxiredoxin 3 (PRDX3), were differentially expressed in PCOS CCs compared with normal CCs (Fig. 6E).
In summary, genes that participate in vital processes such as cell proliferation, hormone receptors signaling, gap communication, folliculogenesis, and oxidative stress were all abnormally expressed in PCOS CCs compared with control CCs at the GV stage, but all of them were recovered to normal levels at the MII stage.

Discussion

The purpose of our study was to use single-cell RNA-sequencing to illuminate differential expression of transcriptome in oocytes and CCs at the GV, MI, and MII stages in women with or without PCOS. Advances in RNA-sequencing technology are obvious compared with microarray methods, and the field of single-cell transcriptome analysis has developed quickly in recent years. Traditional techniques may reflect only the average transcriptome of cells and may yield misleading results. In addition, we showed that our technique has greater sensitivity and coverage than microarray methods after analyzing three samples of individual morula embryos. Last, single-cell RNA-seq can detect heterogeneous single cells such as oocytes and CCs.

RNA-sequencing profiles suggested that genes in PCOS COCs mediated meiosis, hormone receptor signaling, cell-cell communication, proliferation, folliculogenesis, DNA repair, and oxidative stress were differentially expressed at an immature stage. These genes in oocytes were included in the PI3K-Akt signaling pathway, gap junction pathway, calcium signaling pathway, and oocyte meiosis pathway, and genes in CCs were included in the MAPK signaling pathway, steroid hormone biosynthesis pathway, TGF-β signaling pathway, VEGF signaling pathway, and PI3K-Akt signaling pathway. It was found that PI3K-Akt signaling pathway participates in COCs development in PCOS women because this signaling pathway is related to hyperandrogenism, insulin resistance, inflammation and oxidative stress.

Figure 5. Differentially expressed genes in PCOS oocyte studied through single-cell RNA sequencing. The threshold of Padj was set at < 0.05 to find significantly expressed genes. (A) Boxplot showing differentially expressed genes involved in meiosis process. (B) Boxplot showing differentially expressed genes included in gap junction pathway. (C) Boxplot showing differentially expressed genes related to hormone receptor signaling. (D) Boxplot showing differentially expressed genes involved in DNA repairing. (E) Boxplot showing significantly expressed genes are related to secreted factors. *P adj < 0.05. The y axis indicates the log2 (FPKM + 1) expression levels.

In summary, genes that participate in vital processes such as cell proliferation, hormone receptors signaling, gap communication, folliculogenesis, and oxidative stress were all abnormally expressed in PCOS COCs compared with control CCs at the GV stage, but all of them were recovered to normal levels at the MII stage.
Connecting transcriptome profiles with clinical data, these results showed that genes involved in those important processes in PCOS CCs and oocytes were significantly differentially expressed at the GV stage, but with ARTs, the gene expression was comparable in mutational COCs (at the MII stage) between PCOS samples and control samples, which indicates that ARTs could help PCOS patients obtain relatively healthy oocytes at the transcriptome level, as well as a higher ratio of fertilization and cleavage.

Oocyte maturation is promoted by the resumption of meiosis, and inaccurate completion of this process may cause genetic infertility and pregnancy loss. Recent findings indicated that FSH activates EGFR, which can induce oocyte meiosis resumption and maturation through the activation of MAPK3/1. It suggested that EGFR could be used as gene marker of oocyte competence in mammals. PGR and PGRMC1 are nuclear transcription factors that initiate a signaling cascade during the maturation of COCs and are required for cumulus expansion and oocyte meiotic progression. The absence of these transcription factors can arrest oocyte maturation. PLCZ1, which is significantly related to oocyte meiosis and the regulation of insulin secretion, can induce the activation of oocytes at the MII stage so that sperm and oocytes can fuse well. The expression of SFRP4 and ZMIZ1, which are regulators of ovulation and luteinization, is lower in PCOS oocytes, indicating that the abnormal microenvironment of PCOS impacts luteinization negatively. ZSCAN4, a marker for the transition of RNA polymerase II-mediated transcription during GV oocyte maturation, is activated in GV oocyte. In PCOS patients, ZSCAN4 is only downregulated, at GV stage but not MII stage. All of those genes are downregulated in PCOS oocytes at an early stage (Fig. 5), suggesting that PCOS oocyte maturation was delayed at GV stage.

The ITGA gene family is integral transmembrane glycoproteins that connect cells and extracellular matrix, which can send information into cells. Therefore, one function of ITGA genes is the bridge of cell-cell interaction.
cell adhesion, and signal transduction. A previous study demonstrated that \( \text{ITGA9} \) connects with \( \text{ADAM2} \) to mediate sperm-egg interactions and general cell adhesion\(^{32} \). In the current study, the expression of \( \text{ITGA} \) genes was significantly lower in PCOS oocytes than in normal oocytes, including \( \text{ITGA1}, \text{ITGA4}, \text{ITGA6}, \text{ITGA9}, \) and \( \text{ITGA9} \). \( \text{GJA1} \) (CX43), which localizes in gap junctions between oocyte and CCs and participates in primordial follicle assembly, is downregulated in PCOS oocytes, suggesting that oocytes in PCOS patients may not connect well with the surrounding CCs\(^{33} \). Overexpression of \( \text{AMHR2} \) increases the binding of AMH to it, which attenuates follicular or oocyte maturation\(^{34} \). Therefore, \( \text{AMHR2} \) is a possible indicator for the quality of embryo\(^{35} \). In PCOS oocytes, hormone receptors including \( \text{LHCGR}, \text{FSHR}, \text{AMHR2}, \text{KAT2B}, \) and \( \text{OXTR} \) were downregulated in the MII stage, which reflects the ability of oocyte to respond the higher hormone surge and protect the progress of oocyte maturation.

DNA repair pathways are more active in human immature oocytes when double-strand DNA breaks, which may defer meiotic resumption\(^{36} \). DNA-regulating genes such as \( \text{XRCC1}, \text{LIG} \) and \( \text{RAD54L} \) were overexpressed and activated to a higher degree in PCOS oocytes at the GV and MI stages, which can be detected DNA damaging was existed in PCOS women at early stages.

A previous study showed that depletion of \( \text{PPP2R1A} \) leads to an increase the activity of \( \text{CDK1} \) and cyclin B1, maturation promoting factor, which stimulates the transformation of the GV stage to the MI stage\(^{37} \). Therefore, \( \text{PPP2R1A} \) plays a negative role in oocyte meiotic maturation. In our study, PCOS oocytes had a higher expression of \( \text{PPP2R1A} \) than non-PCOS oocytes at the GV and MI stages, which suggested that maturation promoting factor was inhibited, thereby causing oocyte meiosis arrest at the GV and MI stages. \( \text{PGDGRA} \), located in both oocytes and CCs, is a growth factor that positively influences early follicle growth\(^{38} \). The transcription factor \( \text{NOBOX} \) is essential for follicle formation and oocyte survival, and \( \text{NOBOX} \) regulates the expression of \( \text{GDF9} \) in humans, which is a secreted factor that is required for ovarian folliculogenesis\(^{39} \). Summarily, PCOS oocytes have dysfunctional meiosis maturation, gap junction, hormone response, DNA damaging and secreted factors in the early phase. Dysfunction of these genes deferred oocyte meiosis at the GV stage and may inhibit fertilization and other processes. However, these problems can be solved via ARTs according to the expression levels at the MII stage and clinical outcomes.

\( \text{TNFp1P} \)-deficient females are sterile, because this deficiency prevents CCs from assembling with their hyaluronan-rich extracellular matrix\(^{41} \). \( \text{TNFp1P} \), which affects cumulus expansion and oocyte maturation, was overexpressed in PCOS CCs, suggesting acceleration in the maturation of the CCs phenotype\(^{42} \). \( \text{PTGS2} \) increases the expansion of CCs and also plays an important role in the interaction of CCs with oocytes in the periovulatory period\(^{42} \). \( \text{TGF-β} \) is a member of retinoblastoma protein and regulates the proliferation of CCs, and \( \text{CAV1} \) is regulated by LH, and its decreased expression is associated with the deregulation of granulosa cell differentiation\(^{43} \). In mice, downregulation of \( \text{INH/B} \) is shown to significantly increase apoptosis and inhibit steroidogenesis in granulosa cells\(^{44} \). And \( \text{INH/B} \) is upregulated in PCOS CCs, which could have increased the proliferation and steroidogenesis of CCs. Overexpression of \( \text{EGFR} \) in CCs can enhance the proliferation of CCs and oocyte meiosis resumption and maturation through the activation of \( \text{MAPK3} \)\(^{12} \). \( \text{ID3} \) is an AMH target gene and involved in the effects of AMH on the differentiation of CCs, and overexpression of the \( \text{ID3} \) gene inhibits CCs expansion\(^{43} \).

Abnormal proliferation of PCOS granulose cells including CCs has been reported in many previous studies. However, the conclusions of these reports are varied. Several researchers demonstrated the increased proliferation of PCOS granulose cells compared with normal granulose cells, while others found no difference in the proliferation of granulose cells between PCOS and control samples\(^{46,47} \). In our study, the profiles indicated that genes responsible for the proliferation of PCOS CCs were upregulated at the GV stage, which resulted in more immature follicular than normal. But after ARTs, the expression of those genes was restored to its normal level.

\( \text{NOS} \) regulates LH to affect CCs. Higher expression of NOS can cause LH to stimulate the proliferation of CCs\(^{48} \). Recent research showed higher \( \text{SOD1} \) gene expression in CCs in infertile women, which could be a biomarker of clinical pregnancy after Intra- Cytoplasmic Sperm Injection (ICSI)\(^{49} \). Expression of the \( \text{PLA2G4A} \) gene is regulated by LH/hCG-dependent induction in granular cells via the adenylyl cyclase/cAMP pathway; therefore, lower expression of \( \text{PLA2G4A} \) in PCOS CCs reflected an abnormal LH surge\(^{50} \). The LH receptor \( \text{LHCGR} \) allows the development of preovulatory follicle and leads to ovulation. Lower expression of \( \text{LHCGR} \) in PCOS CCs may be a response to increased LH levels, oligomenorrhea, resistance to LH, infertility\(^{51} \). PTGER, the prostaglandin E (PGE) receptor, is expressed in oocytes and CCs. PGE-PTGER signaling regulates CCs expansion and reorganization, which is required for successful sperm attraction, capture, and penetration\(^{52} \). In our study, the expression of both \( \text{PTGER2} \) and \( \text{PTGER4} \) was higher in PCOS GV CCs and enhanced the proliferation of CCs. \( \text{HSDL2}, \text{CYP11A1}, \text{CYP1B1}, \) and \( \text{DHCR24} \) are involved in the production of testosterone in granulosa cells, and upregulation of these enhances testosterone production\(^{53} \). In our study, the expression of these genes was higher in PCOS GV CCs and downregulated in MI and MII, which indicates that testosterone was overproduced mainly at primary follicles.

Genes associated with folliculogenesis are also differentially expressed in PCOS CCs, including \( \text{LMPP2L}, \text{NRPI}, \text{TGF-β}, \) and \( \text{IL}-6 \). \( \text{LMPP2L} \), \( \text{NRPI} \), which enhances follicle assembly, may indicate an oocyte with a positive pregnancy outcome when upregulated in CCs\(^{55} \). The \( \text{TGF-β} \) family, which participates in many processes including folliculogenesis and oocyte maturation, is differentially expressed in PCOS patients compared with non-PCOS patients\(^{56,58} \). We also observed that \( \text{TGF-β} \) was upregulated in PCOS CCs. \( \text{IL}-6 \) is secreted by CCs and promotes COC expansion\(^{59} \).

Notch family members play a role in a variety of developmental processes by controlling cell proliferation, differentiation, and apoptosis, as well as interaction between physically adjacent cells\(^{60} \). In sheep, overexpression of \( \text{NOTCH1} \)-2-3 in granular cells and overexpression of its ligand \( \text{JAG1} \) in oocytes may influence oocyte apoptosis\(^{61} \). Our study showed that \( \text{NOTCH2} \) was significantly overexpressed in PCOS CCs at different stages, which may suggest that an irregular connection existed between CCs and oocytes in PCOS and influenced oocyte maturation. The \( \text{GJA5} \) encoded protein is a component of the gap junction pathway. Activation of \( \text{SIPRI} \) induces
cell-cell adhesion. At the GV stage, these genes were upregulated in PCOS CCs in order to implement atretic oocytes, because gap junction genes in PCOS oocytes were downregulated. SMO is member of the sonic hedgehog pathway and promotes the maturation of COCs by enhancing communication between oocytes and CCs. In our study, we found that some members of the ITGA family were differentially expressed in PCOS CCs; for example, ITGA6 was upregulated in the GV stage but downregulated in the MI and MII stages, which could be explained by the disruption in communication between CCs and oocytes or CCs. Overall, we have shown that in PCOS, the interaction between CCs and CCs or between CCs and oocytes was extremely close when CCs proliferated at an early stage.

FAS contains a death domain and plays a central role in the regulation of programmed cell death. Interaction of the FAS receptor with its ligand accelerates oocyte aging. And SOD1 expression is increased in CCs from infertility women. In our results, upregulation of FAS may have reflected the poor quality of oocytes at the GV stage. GREM1 was significantly downregulated in CCs from diminished ovarian reserve and may be a biomarker of oocyte quality. In Chinese women with PCOS, oxidative stress increases significantly comparing with non-PCOS women because of hyperandrogenism. Previous research has shown that infertility women represented systemic oxidative stress after controlled ovarian stimulation for ARTs. PRDX3 and NDUFA1 are mitochondrial antioxidants, and previous research suggested that these genes are upregulated in response to oxidative stress and endoplasmic reticulum stress in CCs, which may accelerate aging. Therefore, at the GV stage, PCOS CCs had higher expression of PRDX3 and NDUFA1, which suggests that the CCs had suffered oxidative damage.

To our knowledge, our study is the first time to analyze the transcriptome level of PCOS COCs at the GV, MI, and MII stages via single-cell RNA-seq. Due to the poor quality of oocytes and arrest of follicular development in PCOS patients, subfertility has become a significant problem in this population, and ARTs are considered third-line treatment. However, the effect of ARTs is not yet clear because opinions about it are contradictory. Therefore, we sought to assess the effect of ART in PCOS COGs both at the transcriptome level and via clinical statistics. Our findings indicate that ARTs not only can induce ovulation in PCOS patients but also repair the poor quality of oocytes at the transcriptome level and increase the ratio of fertilization and cleavage and the quality of embryos. Moreover, our work revealed several causes of subfertility in PCOS patients at an early stage. Firstly, the development of PCOS oocytes is delayed because of lower expression of genes associated with meiosis, gap junction, hormone receptors signaling, and secreted factors. Secondly, higher expression of genes associated with DNA repair in PCOS oocytes is the response to the poor environment for oogenesis and could also reflect the inferior quality of PCOS oocytes relative to control oocytes at an early stage. Thirdly, we identified genes associated with cell-cell communication, proliferation, hormone receptor signaling, folliculogenesis, and oxidative stress in PCOS CCs. Finally, the PI3K-Akt signaling pathway, gap junction pathway, calcium signaling pathway, oocyte meiosis pathway, MAPK signaling pathway, steroid hormone biosynthesis pathway, TGF-β signaling pathway, and VEGF signaling pathway may play a vital role in the development of COCs, because most of the differentially expressed genes we identified were involved in these pathways. In conclusion, ARTs can be an effective treatment for subfertile patients with PCOS.

Materials and Methods

We recruited 42 women with PCOS and 42 women without PCOS, all of whom were undergoing gonadotropin therapy at Anhui First People’s Hospital in Anhui, China. We have recorded several clinical outcomes of these participants and then compared rates of outcomes between with and without PCOS women. Among them, 9 women with PCOS and 7 women without PCOS were willing to donate COCs for research. PCOS patients were confirmed to have at least two of three Rotterdam 2003 criteria for diagnosing PCOS: hyperandrogenism, oligoovulation and/or anovulation, and polycystic ovaries. All control patients had regular menstrual cycles, normal luteal serum progesterone levels, and normal ovarian morphology. We excluded patients with Cushing’s syndrome, congenital adrenal hyperplasia, and androgen-secreting tumors. Spouses of participants were not infertile. Stimulation protocol for all the patients was according to the standard long protocol. Patients’ demographic and clinical characteristics such as age, BMI, LH, FSH and rate of oocytes fertilization, cleavage and embryo were also collected. The study protocol was approved by the Research Ethics committee of Anhui First People’s Hospital (No: 2014008) and conducted in accordance with approved institutional guidelines. All participants gave written informed consent.

Oocyte Retrieval and Isolation of CCs.

Ovarian stimulation and oocyte retrieval protocols were carried out based on the Rotterdam European Society for Human Reproduction/American Society of Reproductive Medicine-Sponsored PCOS Consensus. COCs were isolated via ultrasound-guided vaginal puncture and categorized according to the oocyte nuclear maturation stage: GV, MI, or MII.

We collected 11 oocytes from non-PCOS patients and 9 oocytes from women with PCOS (Table 3). About 10 CCs were isolated from each oocyte. A total of 28 CCs groups were isolated from the oocytes with PCOS and with non-PCOS. Based on the Smart-seq2 protocol, each oocyte or about 10 CCs picked up randomly were transferred to a tube with lysis buffer and stored at −80 °C for RNA-seq.

|           | GV (oocyte/CC) | MI (oocyte/CC) | MII (oocyte/CC) |
|-----------|----------------|----------------|-----------------|
| Normal    | 3/3            | 4/5            | 4/6             |
| PCOS      | 3/4            | 3/6            | 3/4             |

Table 3. Numbers of oocyte and cumulus cells at different stages analyzed by single-cell RNA-sequencing.
Library Construction and Sequencing. We referred to the Smart-seq2 protocol for all RNA-seq experiments\(^2\). Single cells were washed twice with 1XPBS before being placed in lysis buffer. RNA was isolated from single cells and converted into cDNA. Library construction was performed following the Smart-seq2 protocol, and sequenced on an Illumina HiSeq2500 sequencer. Data normalization was carried out by transforming mapped transcript reads to fragments per kilobase of transcript per million mapped reads (FPKM). Genes with fragments per kilobase of transcript per million mapped reads (FPKM) > 0.5 were retained for analysis.

Gene Expression Analysis and Statistics. Genes under threshold of \( P_{adj} < 0.05 \) were called differentially expressed between samples. \( P_{adj} \) was calculated via a Benjamini-Hochberg method to exclude false positive results. All clinic parameters were expressed as mean values ± standard deviation (SD). Pathway enrichment analysis was performed using the DAVID web tool\(^7\). When it showed \( P_{adj} < 0.05 \), it can be considered as significant pathway. Heatmap was constructed using heatmap.2 function (gplots package) of R. To identify differentially expressed genes in different stages, we used R package gplots to analyze expression levels of selected genes in each group. Clinical outcomes between PCOS group and control group were tested by t-test and Mann-Whitney U test in the software SPSS20.0. Data of age, FSH, androstenedione and percent of high-quality embryo were normal distribution (Shapiro-Wilk, Sig. > 0.05), so t-test of independent sampler was used to analyze the scores of those groups. Because the data of BMI, SBP, DPB, LH, LH/FSH, SHBG, total gonadotropin dose, testosterone, insulin, ovarian volume total (right and left), number of aspirated oocyte, percent of mature oocyte, percent of oosperm, and percent of cleavage were not normal distribution (Shapiro-Wilk, Sig. > 0.05 or Levene's Test, Sig. > 0.05), we used Mann-Whitney U test to analyze the scores of those groups.

References
1. Toulis, K. A. et al. Adiponectin levels in women with polycystic ovary syndrome: a systematic review and a meta-analysis. *Hum Reprod Update* 15, 297–307, doi: 10.1093/humupd/dmp006 (2009).
2. Savaris, R. F. et al. Progesterone resistance in PCOS endometrium: a microarray analysis in clomiphene citrate-treated and artificial menstrual cycles. *J Clin Endocrinol Metab* 96, 1737–1746, doi: 10.1210/jc.2010-2600 (2011).
3. Perales-Puchalt, A. & Legro, R. S. Ovulation induction in women with polycystic ovary syndrome. *Stemoids* 78, 767–772, doi: 10.1001/j.j.2013.03.005 (2013).
4. Ashrafi, M., Kiani, K., Ghasemi, A., Rastegar, F. & Nabavi, M. The effect of low dose human chorionic gonadotropin on follicular response and oocyte maturation in PCOS patients undergoing IVF cycles: a randomized clinical trial of efficacy and safety. *Arch Gynecol Obstet* 284, 1431–1438, doi: 10.1007/s00404-010-1827-0 (2011).
5. Nahuiss, M. J. et al. Long-term outcomes in women with polycystic ovary syndrome initially randomized to receive laparoscopic electrocautery of the ovaries or ovulation induction with gonadotrophins. *Hum Reprod* 26, 1899–1904, doi: der141 [pii]10.1093/humrep/der141 [doi] (2011).
6. Wang, F., Dai, W., Yang, X. H., Guo, Y. H. & Sun, Y. P. Analyses of optimal body mass index for infertile patients with either polycystic or non-polycystic ovary syndrome during assisted reproductive treatment in China. *Scientific reports* 6, 34538, doi: srep34538 [pii]10.1038/srep34538 [doi] (2016).
7. Siristatidis, C. et al. In Vitro Maturation in Women with vs. without Polycystic Ovarian Syndrome: A Systematic Review and Meta-Analysis. *PlosOne* 10, e0134696, doi: 10.1371/journal.pone.0134696 (2015).
8. Heijnen, E. M. et al. A meta-analysis of outcomes of conventional IVF in women with polycystic ovary syndrome. *Hum Reprod Update* 12, 13–21, doi: 10.1093/humupd/dmi036 (2006).
9. Qiao, J. & Feng, H. L. Extra- and intra-ovarian factors in polycystic ovary syndrome: impact on oocyte maturation and embryo developmental competence. *Hum Reprod Update* 17, 17–33, doi: 10.1093/humupd/dmp032 (2011).
10. Junk, S. M. & Yeap, D. Improved implantation and ongoing pregnancy rates after single-embryo transfer with an optimized protocol for in vitro embryo maturation in women with polycystic ovaries and polycystic ovary syndrome. *Fertility and sterility* 98, 888–892, doi: 10.1016/j.fertnstert.2012.06.055 (2012).
11. Sigala, J. et al. Is polycystic ovarian morphology related to a poor oocyte quality after controlled ovarian hyperstimulation for intracytoplasmic sperm injection? Results from a prospective, comparative study: *Fertility and sterility* 103, 112–118, doi: 10.1016/j.fertnstert.2014.09.040 (2015).
12. Younis, J. S., Jadaon, J. E., Haddad, S., Izhaki, I. & Ben-Ami, M. Prospective evaluation of basal stromal Doppler studies in women with good ovarian reserve and infertility undergoing in vitro fertilization-embryo transfer treatment: patients with polycystic ovary syndrome versus ovulatory patients. *Fertility and sterility* 95, 1754–1758, doi: 10.1016/j.fertnstert.2011.01.007 (2011).
13. Ouandaogo, Z. G. et al. Differences in transcriptomic profiles of human cumulus cells isolated from oocytes at GV and MII stages after in vitro and in vitro oocyte maturation. *Hum Reprod* 27, 2438–2447, doi: 10.1093/humrep/des172 (2012).
14. Huang, X. et al. Differences in the transcriptional profiles of human cumulus cells isolated from MI and MII oocytes of patients with polycystic ovary syndrome. *Reproduction (Cambridge, England)* 145, 597–608, doi: 10.1530/rep-13-0005 (2013).
15. Lan, C. W. et al. Functional microarray analysis of differentially expressed genes in granulosa cells from women with polycystic ovary syndrome related to MAPK/ERK signaling. *Scientific reports* 5, 14994, doi: 10.1038/srep14994 (2015).
16. Kenigsberg, S. et al. Gene expression microarray profiles of cumulus cells in lean and overweight-obese polycystic ovary syndrome patients. *Molecular human reproduction* 15, 89–103, doi: 10.1039/molehr/gan0082 (2009).
17. Ouandaogo, Z. G. et al. Human cumulus cells molecular signature in relation to oocyte nuclear maturity stage. *PloS One* 6, e27179, doi: 10.1371/journal.pone.0027179 (2011).
18. Shalek, A. K. et al. Single-cell transcriptomics reveals bimodality in expression and splicing in immune cells. *Nature* 498, 236–240, doi: 10.1038/nature12172 (2013).
19. Xue, Z. et al. Genetic programs in human and mouse early embryos by revealed single-cell RNA sequencing. *Nature* 500, 593–597, doi: 10.1038/nature12364 (2013).
20. Luo, Y. et al. Single-cell transcriptome analyses reveal signals to activate dormant neural stem cells. *Cell* 161, 1175–1186, doi: 10.1016/j.cell.2015.04.001 (2015).
21. Li, T. et al. Role of the PI3K-Akt Signaling Pathway in the Pathogenesis of Polycystic Ovary Syndrome. *Reproductive sciences (Thousand Oaks, Calif).* doi: 10.1177/1933719116676006 (2016).
22. Hassold, T. & Hunt, P. To err (meiotically) is human: the genesis of human aneuploidy. *Nat Rev Genet* 2, 280–291, doi: 10.1038/35066065 [doi]35066065 [pii] (2001).
23. Yang, L. et al. NPR2 is involved in FSH-mediated mouse oocyte meiotic resumption. *Journal of ovarian research* 9, 6, doi: 10.1186/s13048-016-0218-y (2016).
59. Assou, S. et al. Cultured Cells from the Human Oocyte Cumulus Niche Are Efficient Feeders to Propagate Pluripotent Stem Cells. *Stem cells and development* **24**, 2317–2327, doi: 10.1089/scd.2015.0043 (2015).

60. Artavanis-Tsakonas, S., Rand, M. D. & Lake, R. J. Notch signaling: cell fate control and signal integration in development. *Science* **284**, 770–776 (1999).

61. Xu, J. & Gridley, T. Notch2 is required in somatic cells for breakdown of ovarian germ-cell nests and formation of primordial follicles. *BMC Biol* **11**, 13, doi: 1741-7007-11-13 [pii]10.1186/1741-7007-11-13 [doi] (2013).

62. Nguyen, N. T. et al. Sonic hedgehog promotes porcine oocyte maturation and early embryo development. *Reproduction, fertility, and development* **21**, 805–815, doi: 10.1071/rd08277 (2009).

63. Zhu, J. et al. Cumulus cells accelerate oocyte aging by releasing soluble Fas ligand in mice. *Scientific reports* **5**, 8683, doi: 10.1038/srep08683 (2015).

64. Ovarian tissue cryopreservation: a committee opinion. *Fertility and sterility* **101**, 1237–1243, doi: 10.1016/j.fertnstert.2014.02.052 (2014).

65. Jindal, S., Greensheid, K., Berger, D., Santoro, N. & Pal, L. Impaired gremlin 1 (GREM1) expression in cumulus cells in young women with diminished ovarian reserve (DOR). *J Assist Reprod Genet* **29**, 159–162, doi: 10.1007/s10815-011-9684-8 [doi] (2012).

66. Zhang, R. et al. Oxidative stress status in Chinese women with different clinical phenotypes of polycystic ovary syndrome. *Clin Endocrinol (Oxf)*, doi: 10.1111/cen.13171 (2016).

67. Melo, A. S., Khemchen, J., Junior, A. A., Ferranti, R. A. & Navarro, P. A. Oxidative stress and polycystic ovary syndrome: evaluation during ovarian stimulation for ICSI. *Reproduction (Cambridge, England)*, doi: 10.1530/REP-16-0084 (2016).

68. Lim, J. & Luderer, U. Oxidative damage increases and antioxidant gene expression decreases with aging in the mouse ovary. *Biology of reproduction* **84**, 775–782, doi: 10.1095/biolreprod.110.088583 (2011).

69. Azziz, R. et al. Polycystic ovary syndrome. *Nat Rev Dis Primers* **2**, 16057, doi: nrpd201657 [pii]10.1038/nrdp.2016.57 [doi] (2016).

70. Rotterdam, E. A.-S. P. C. W. G. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). *Hum Reprod* **19**, 41–47 (2004).

71. Rotterdam, E. A.-S. P. C. W. G. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. *Fertil Steril* **81**, 19–25 (2004).

72. Picelli, S. et al. Full-length RNA-seq from single cells using Smart-seq2. *Nat Protoc* **9**, 171–181, doi: nprot.2014.006 [pii]10.1038/nprot.2014.006 [doi] (2014).

73. Huang, da, W., Sherman, B. T. & Lempicki, R. A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. *Nat Protoc* **4**, 44–57, doi: nprot.2008.211 [pii]10.1038/nprot.2008.211 [doi] (2009).

**Acknowledgements**

This study was supported by grants from National Natural Science Foundation of China (Key Program 81430026); Shanghai Municipal Commission of Health and Family Planning (XBR2013094); Jiangsu Science and Technology Commission of HUNAN Province Plan (2060403); Science and Technology Commission of Shanghai Municipality (16JC1404700); and Development and Reform Commission Project (BM2014052); The National Key Research and Development Plan (2016YFC1000208); Shanghai Municipal Commission of Health and Family Planning (XBR2013094); Jiangsu Science and Technology Commission of HUNAN Province Plan (2060403).

**Author Contributions**

Q.W.L. performed experiments and wrote paper; Y.M.L. and H.F.X. analyzed clinical data; Y.X.C. and Y.Z.J. provided samples; Y.F.L. collected samples; Y.F. and J.L.M. analyzed single-cell RNA sequencing; C.J.L. used SPSS to make statistics; X.W.T. and Z.G.X. obtained funding and designed the research. All authors reviewed the manuscripts.

**Additional Information**

**Competing financial interests:** The authors declare no competing financial interests.

**How to cite this article:** Liu, Q. et al. Single-cell analysis of differences in transcriptomic profiles of oocytes and cumulus cells at GV, MI, MI stages from PCOS patients. *Sci. Rep.* **6**, 39638; doi: 10.1038/srep39638 (2016).

**Publisher’s note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

© The Author(s) 2016